Antitumor efficacy of solid dispersion of paclitaxel prepared by supercritical antisolvent process in human mammary tumor xenografts

International Journal of Pharmaceutics

Volumn 403, Issue 1-2, 2011, Pages 130-135

  Shanmugam, Srinivasan ^a   Park, Jae Hyun ^a   Chi, Sang Cheol ^b   Yong, Chul Soon ^c   Choi, Han Gon ^d   Woo, Jong Soo ^a  

^a Hanmi Pharmaceutical Co Ltd   (South Korea)

^b Sungkyunkwan University   (South Korea)

^c Yeungnam University   (South Korea)

^d Hanyang University   (South Korea)

Author keywords

Antitumor efficacy; Mammary tumor xenografts; Paclitaxel; Solid dispersion; Supercritical antisolvent process

Indexed keywords

DRUG CARRIER; PACLITAXEL; PACLITAXEL SOLID DISPERSION; POLYMER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST TUMOR; CANCER INHIBITION; CANCER RECURRENCE; CANCER SURVIVAL; CANCER SURVIVOR; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG FORMULATION; DRUG SYNTHESIS; DRUG TOLERABILITY; FEMALE; HYDROPHILICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUPERCRITICAL ANTISOLVENT; TUMOR REGRESSION; TUMOR XENOGRAFT; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CARRIERS; DRUG COMPOUNDING; FEMALE; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, NUDE; PACLITAXEL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 78650178767     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2010.10.033     Document Type: Article

References (33)

1. J.M. Aceves, R. Cruz, and E. Hernandez Preparation and characterization of Furosemide-Eudragit controlled release systems Int. J. Pharm. 195 2000 45 53
2. J.D. Adams, K.P. Flora, B.R. Goldspiel, J.W. Wilson, S.G. Arbuck, and R. Finley Taxol: a history of pharmaceutical development and current pharmaceutical concerns J. Natl. Cancer Inst. Monogr. 15 1993 141 147
3. ® Pharm. Res. 11 1994 206 212
4. S.G. Arbuck, R. Canetta, N. Onetto, and M.C. Christian Current dosage and schedule issues in development of paclitaxel (Taxol) Semin. Oncol. 20 1993 31 39
5. E. Bilensoy, O. Gurkaynak, A.L. Dogan, and A.A. Hincal Safety and efficacy of amphiphilic ß-cyclodextrin nanoparticles for paclitaxel delivery Int. J. Pharm. 347 2008 163 170
6. N. Desai, V. Trieu, Z. Yao, L. Louie, S. Ci, A. Yang, C. Tao, T. De, B. Beals, D. Dykes, P. Noker, R. Yao, E. Labao, M. Hawkins, and P. Soon-Shiong Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of Cremophor-free, albumin-bound paclitaxel, BI-007, compared with Cremophor-based paclitaxel Clin. Cancer Res. 12 2006 1317 1324
7. ® encapsulation in poly(ε-caprolacton) microspheres Cancer Chemother. Pharmacol. 36 1995 279 282
8. Z. Feng, G. Zhao, L. Yu, D. Gough, and S.B. Howell Preclinical efficacy studies of a novel nanoparticle-based formulation of paclitaxel that out-performs Abraxane Cancer Chemother. Pharmacol. 65 2010 923 930
9. W.J. Gradishar, S. Tjulandin, N. Davidson, H. Shaw, N. Desai, P. Bhar, M. Hawkins, and J. O'Shaughnessy Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer J. Clin. Oncol. 23 2005 7794 7803 (Pubitemid 46657376)
10. F.A. Holmes, R.S. Walters, R.L. Theriault, A.U. Buzdar, D.K. Frye, G.N. Hortobagyi, A.D. Forman, L.K. Newton, and M.N. Raber Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer J. Natl. Cancer Inst. 83 1991 1797 1805
11. ®) and metabolites in a randomized comparative study in platinum pretreated ovarian cancer patients J. Clin. Oncol. 11 1993 2127 12127
12. J. Jung, and M. Perrut Particle design using supercritical fluids: literature and patent survey J. Supercrit. Fluids 20 2001 179 219
13. S.K. Kim, D.W. Kim, Y.H. Shim, J.S. Bang, H.S. Oha, S.W. Kim, and M.H. Seo In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy J. Control. Release 72 2001 191 202
14. U.B. Kompella, and K. Koushik Preparation of drug delivery systems using supercritical fluid technology Crit. Rev. Ther. Drug Carrier Syst. 18 2001 173 199
15. J.M. Koziara, T.R. Whisman, M.R. Tseng, and R.J. Mumper In-vivo efficacy of novel paclitaxel nanoparticles in paclitaxel-resistant human colorectal tumors J. Control. Release 112 2006 312 319
16. L.Y. Lee, C.H. Wang, and K.A. Smith Supercritical antisolvent production of biodegradable micro- and nanoparticles for controlled delivery of paclitaxel J. Control. Release 125 2008 96 106
17. T. Matsumoto, and G. Zografi Physical properties of solid molecular dispersions of indomethacin with poly(vinylpyrrolidone) and poly(vinylpyrrolidone-co-vinyl-acetate) in relation to indomethacin crystallization Pharm. Res. 16 1999 1722 1728
18. M. Miyazaki, N. Lamharzi, A.V. Schally, G. Halmos, K. Szepeshazi, K. Groot, and R.Z. Cail Inhibition of growth of MDA-MB-231 human breast cancer xenografts in nude mice by bombesin/gastrin-releasing peptide (GRP) antagonists RC-3940-II and RC-3095 Eur. J. Cancer 34 1998 710 717
19. M.P. Oth, and A.J. Moes Sustained release solid dispersions of indomethacin with Eudragit RS and RL Int. J. Pharm. 55 1989 157 174
20. R. Panchagnula Pharmaceutical aspects of paclitaxel Int. J. Pharm. 172 1998 1 15
21. J.H. Park, S.C. Chi, and J.S. Woo Preparation and evaluation of paclitaxel solid dispersion by supercritical antisolvent process J. Kor. Pharm. Sci. 38 2008 241 247
22. J.H. Park, S.C. Chi, W.S. Lee, W.M. Lee, Y.B. Koo, C.S. Yong, H.G. Choi, and J.S. Woo Toxicity studies of Cremophor-free PTX solid dispersion formulated by a supercritical antisolvent process Arch. Pharm. Res. 32 2009 139 148
23. ® Int. J. Pharm. 218 2001 27 42
24. J. Riondel, M. Jacrot, F. Picot, H. Beriel, C. Mouriquand, and P. Potier Therapeutic response to Taxol of six human tumors xenografted into nude mice Cancer Chemother. Pharmacol. 17 1986 137 142
25. E.K. Rowinsky, L.A. Cazenave, and R.C. Donehower Taxol: a novel investigational antimicrotubule agent J. Natl. Cancer Inst. 82 1990 1247 1259
26. E.K. Rowinsky, and R.C. Donehow Paclitaxel (Taxol) N. Engl. J. Med. 332 1995 1004 1014
27. E.K. Rowinsky, and R.G. Donehower Drug therapy-paclitaxel (taxol) New Engl. J. Med. 332 1995 1004 1014
28. M.F. Shieh, I.M. Chu, C.J. Lee, P. Kan, D.M. Hau, and J.J. Shieh Liposomal delivery system for taxol J. Ferment. Bioeng. 83 1997 12 15
29. B.D. Tarr, T.G. Sambandan, and S.H. Yalkowsky A new parenteral emulsion for the administration of taxol Pharm. Res. 4 1987 162 165
30. L.S. Taylor, and G. Zografi Spectroscopic characterization of interactions between PVP and indomethacin in amorphous molecular dispersions Pharm. Res. 14 1997 1691 1698
31. E.M. Wall, and M.C. Wani Camptothecin and taxol: discovery to clinic-thirteenth Bruce F. Cain memorial award lecture Cancer Res. 55 1995 753 760
32. ® J. Clin. Oncol. 8 1990 1263 1271
33. T. Yano, J. Pinski, K. Groot, and A.V. Schally Stimulation by bombesin and inhibition by bombesin/gastrin-releasing peptide antagonist RC-3095 of growth of human breast cancer cell lines Cancer Res. 52 1992 4545 4547